StuffThatWorks Taps Veteran Caroline Redeker to Reshape Drug Trials

TEL AVIV, Israel – May 07, 2026 – In a strategic move signaling an aggressive push to overhaul clinical research, AI-driven health data company StuffThatWorks today announced the appointment of Caroline Redeker as its new Chief Commercial Officer. The 30-year industry veteran joins the firm at a pivotal moment, tasked with commercializing a platform that promises to slash drug development timelines by leveraging vast, AI-organized patient experiences.

Redeker’s appointment is more than a high-profile hire; it represents the fusion of deep industry expertise with cutting-edge technology aimed at solving one of pharma's most intractable problems: a clinical trial system plagued by inefficiency, staggering costs, and a disconnect from the patients it aims to serve. As StuffThatWorks seeks to scale its unique model in the U.S. market, Redeker’s leadership is positioned as the key to unlocking its disruptive potential.

The Billion-Dollar Bottleneck in Drug Development

The pharmaceutical industry operates under immense pressure to innovate, yet the process of bringing a new treatment to market remains notoriously slow and expensive. The average cost to develop a single drug now hovers around a staggering $2.6 billion. A significant portion of this expense is tied to clinical trials, a phase where progress is often measured in years and setbacks are common.

Industry data paints a grim picture: over 70% of clinical trials face delays, often due to challenges in recruiting enough of the right patients. Increasingly complex study protocols contribute to these hurdles, leading to feasibility failures that can derail a trial before it even gains momentum. The financial consequences are severe. A single day of delay for a promising therapeutic can represent a loss of anywhere from $600,000 to over $1 million in potential revenue, with some analyses placing the total unrealized sales and direct costs at nearly $840,000 per day.

At the heart of this inefficiency is a fundamental data problem. Historically, trial design and execution have relied on data from medical records, insurance claims, or small, slow surveys—sources that often provide an incomplete or lagging picture of a patient's actual lived experience. This gap in real-world insight contributes directly to protocol failures and recruitment struggles, as trials are designed without a full understanding of the patient journey.

A New Paradigm: AI-Powered Patient Intelligence

StuffThatWorks proposes a radical alternative built from the ground up. The company has developed what it calls the world's first AI-native, patient-driven data foundation. By engaging directly with patients through smart crowdsourcing, the platform has amassed over 1.3 billion structured, longitudinal data points from a community of more than 3 million people across 1,250 different health conditions.

Unlike competitors that primarily rely on de-identified EHR or claims data, StuffThatWorks transforms the qualitative, day-to-day experiences of patients—their symptoms, treatment successes and failures, and side effects—into standardized, structured, and research-grade data. The company states its data is SNOMED interoperable, a global standard for clinical terminology, and IRB-approved, positioning it for serious scientific and commercial use. This AI-ready dataset provides a rich, dynamic resource for pharmaceutical and life sciences partners, enabling them to optimize trial protocols, identify new uses for existing drugs, and gather commercial intelligence with unprecedented speed and depth.

The company's ultimate promise is an integrated clinical trial flow—from protocol design and patient recruitment through trial execution and real-world evidence generation—that can be up to twice as fast as the traditional model. To bolster its claims of data quality, the firm recently launched a Research Fellows Program, granting non-profit researchers independent access to its datasets to accelerate scientific publication.

Veteran Leadership for a Disruptive Technology

Bringing such a disruptive technology to a conservative industry requires a leader with credibility and an intimate understanding of the market's pain points. In Caroline Redeker, StuffThatWorks has found a CCO who has spent her career navigating the complexities of clinical research.

Her most recent 14-year tenure as Chief Strategy & Commercial Officer at Advanced Clinical saw her drive significant revenue growth and market expansion. A recognized innovator and PharmaVoice 100 recipient, Redeker has built and scaled CRO businesses and understands the operational challenges of drug development firsthand.

“Caroline is exactly the caliber of commercial leader this moment calls for,” said Julie A. Ross, CEO and President of StuffThatWorks. “Her decades of experience building and scaling CRO businesses and commitment to advancing options for patients, make her uniquely positioned to bring our platform’s value to the pharma and life sciences organizations that need it most.”

Redeker’s appointment is the latest move in a broader strategy to build a world-class commercial leadership team. It follows the hiring of Ross, herself a former CRO executive, as CEO in November 2025. This deliberate recruitment of seasoned leaders from the traditional clinical research world underscores the company's focus on bridging the gap between its technological innovation and the practical needs of its target customers.

For her part, Redeker views the platform as a solution to problems she has long confronted. “I’ve spent my career trying to get closer to what patients actually experience, and StuffThatWorks has built something I’ve never seen before: a platform that puts that patient experience and engagement at the center of clinical development,” Redeker stated. “The problems this solves are ones I’ve experienced firsthand: protocol failures, recruitment delays, insufficient real-world insight. I’m proud to join a team that is redefining how the industry operates.”

As CCO, her primary objective will be to translate the platform's vast data-generating capabilities into tangible, commercial solutions for an industry hungry for efficiency. Her role will be central to shaping how the company grows and demonstrates its value proposition to pharma and biotech partners.

The company is set to showcase its vision to a key audience of investors and innovators later this month. Leadership will host a fireside chat during the Bio-IT World Venture, Innovation and Partnering Summit in Boston on May 19, an event that convenes leaders focused on accelerating science and advancing precision medicine.